Novartis reshuffles its $9B R&D operation to save $1B a year

Damian Garde

Swiss pharma giant is changing up its massive R&D organization in hopes of squeezing out some savings while betting big on new medicines.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS